Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Other 1

Conditions

Obesity 9Endometrial Neoplasms 5Prostatic Neoplasms 2Overweight 2Endometrial Hyperplasia 2Diabetes Mellitus 2Breast Neoplasms 2Weight Loss 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Opioid-Related Disorders 1Metabolic Syndrome 1Lymphoma, Follicular 1Insulin Resistance 1Inflammation 1Hyperplasia 1Dyslipidemias 1Colorectal Neoplasms 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × Tirzepatide × Clear all
NCT07257484 2026-03-13

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

Weill Medical College of Cornell University

Phase 4 Not yet recruiting
30 enrolled
BreastOther

Breast Neoplasms, Obesity

NCT06517212 2026-02-12

TRIM-EBC

Baylor Research Institute

Phase 2 Recruiting
48 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡